Table 1.
Experimental time points, array and RNA-seq platforms and number of individuals analysed in the study.
| Days | Time point | Arrays (N) | RNA-seq (N) |
|---|---|---|---|
| − 14 | Base1 | HT12v4 (18); HTA2.0 (10) | Illumina (10); MGI (10) |
| − 1 | Base2 | HT12v4 (18); HTA2.0 (10) | Illumina (10); MGI (10) |
| 2 | EPO3 | HT12v4 (18); HTA2.0 (10) | Illumina (10); MGI (10) |
| 14 | EPO4 | HT12v4 (18); HTA2.0 (10) | Illumina (10); MGI (10) |
| 28 | EPO5 | HT12v4 (18); – | – |
| + 7 | Post6 | HT12v4 (18); – | – |
| + 14 | Post7 | HT12v4 (18); HTA2.0 (10) | Illumina (10); MGI (10) |
| + 28 | Post8 | HT12v4 (18); – | – |
Samples collected across all eight time points were previously subjected to analysis on the HT12v4, and the raw intensities were re-analysed in the current study. Base1 severed as the baseline for gene expression comparisons. N: the number of individuals. HT12v4: illumina HumanHT-12 v4 expression BeadChip; HTA2.0: GeneChip HTA2.0; Illumina: Illumina NextSeq 500; MGI: MGI DNBSEQ-G400RS. –: not applicable.